CERT
Get informed when a big investor buys or sells
+ FollowOvervalued by 5.4% based on the discounted cash flow analysis.
| Market cap | $1.30 Billion |
|---|---|
| Enterprise Value | $1.48 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.01 |
| Beta | 1.41 |
| Outstanding Shares | 154,356,779 |
| P/E Ratio | -18.83 |
|---|---|
| PEG | -0.7 |
| Price to Sales | 4.14 |
| Price to Book Ratio | 1.38 |
| Enterprise Value to Revenue | 3.63 |
| Enterprise Value to EBIT | 51.62 |
| Enterprise Value to Net Income | -22 |
| Total Debt to Enterprise | 0.25 |
| Debt to Equity | 0.38 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 2.89% |
|---|---|
| Total Calls | 164,800▼ 58.15% |
| Total Puts | -▼ 100.00% |
Holdings and activity of institutional investors.
| Ownership % | 86.32%▲ 2.13% |
|---|---|
| Total Invested | $1.01B▲ 31.34% |
| Investors Holding | 244▼ 15.00% |
No data
Certara optimizes R&D productivity, commercial value and patient outcomes through its unique portfolio of model-informed drug development, regulatory science, and market access solutions. In fact, 90+% of all novel drugs approved by the ...